ScholarIQanswers from OpenAlex
University of Colorado Cancer Center
InstitutionResearch output, impact & collaborations
University of Colorado Cancer Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about University of Colorado Cancer Center?
ScholarIQrecord summary
University of Colorado Cancer Center is a research organisation in Aurora, US. OpenAlex records 6,500 works and 1,036,842 citations for it. 913 researchers list it as their most recent affiliation.
How many works does University of Colorado Cancer Center have?
ScholarIQindexed works
University of Colorado Cancer Center has 6,500 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does University of Colorado Cancer Center have?
ScholarIQcitation count
University of Colorado Cancer Center has 1,036,842 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at University of Colorado Cancer Center?
ScholarIQresearcher count
University of Colorado Cancer Center has 913 researchers in the ScholarIQ index.
What is the average h-index at University of Colorado Cancer Center?
ScholarIQavg h-index
University of Colorado Cancer Center has an average h-index of 73.8 in OpenAlex.
What is the ROR of University of Colorado Cancer Center?
ScholarIQror
The ROR for University of Colorado Cancer Center is on the source record.
What is the OpenAlex record for University of Colorado Cancer Center?
ScholarIQopenalex
The OpenAlex for University of Colorado Cancer Center is on the source record.
Who are the most-cited researchers behind University of Colorado Cancer Center?
ScholarIQtop researchers by citations
What are the most-cited papers on University of Colorado Cancer Center?
ScholarIQmost cited works
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Paul N. Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, H. Suttmann, Winald R. Gerritsen, Thomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan J. Pantuck, Eric Winquist, Celestia S. Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf
Who collaborates most closely around University of Colorado Cancer Center?
ScholarIQco-authorship network
United States
100%
MOST FREQUENT PARTNER INSTITUTIONS
How much of the research on University of Colorado Cancer Center is open access?
ScholarIQopen access share
50%OPEN ACCESS